APA

Lotery A., Sivaprasad S., O'Connell A., Harris R. A., Culliford L., Ellis L., Cree A., Madhusudhan S., Behar-Cohen F., Chakravarthy U., Peto T., Rogers C. A. & Reeves B. C. (20200206). Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. : Lancet (London, England).

Chicago

Lotery Andrew, Sivaprasad Sobha, O'Connell Abby, Harris Rosie A, Culliford Lucy, Ellis Lucy, Cree Angela, Madhusudhan Savita, Behar-Cohen Francine, Chakravarthy Usha, Peto Tunde, Rogers Chris A and Reeves Barnaby C. 20200206. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. : Lancet (London, England).

Harvard

Lotery A., Sivaprasad S., O'Connell A., Harris R. A., Culliford L., Ellis L., Cree A., Madhusudhan S., Behar-Cohen F., Chakravarthy U., Peto T., Rogers C. A. and Reeves B. C. (20200206). Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. : Lancet (London, England).

MLA

Lotery Andrew, Sivaprasad Sobha, O'Connell Abby, Harris Rosie A, Culliford Lucy, Ellis Lucy, Cree Angela, Madhusudhan Savita, Behar-Cohen Francine, Chakravarthy Usha, Peto Tunde, Rogers Chris A and Reeves Barnaby C. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. : Lancet (London, England). 20200206.